GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms (TAMBE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02528500 |
Recruitment Status :
Completed
First Posted : August 19, 2015
Results First Posted : July 3, 2018
Last Update Posted : June 28, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Thoracoabdominal Aortic Aneurysm | Device: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Early Feasibility Assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels |
Actual Study Start Date : | November 2015 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | February 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: TAMBE Device
Study designed to assess the feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in the treatment of patients with aortic aneurysms involving the visceral branch vessels. Patients with thoracoabdominal or pararenal abdominal aortic aneurysms are eligible for screening for participation in the study. The particular characteristics of the patient's aneurysm and anatomy will determine ultimate eligibility for enrollment. Only patients who meet all of the eligibility criteria will be enrolled.
|
Device: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
Other Name: TAMBE Device |
- Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood Loss ≥1000 mL [ Time Frame: Absence of procedural safety events through 30 days post procedure ]Absence of the following procedural safety events through 30 days post-procedure: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood Loss ≥1000 mL
- Technical Success, Including Individual Components of Technical Success [ Time Frame: 12-month ]Components of Technical Success: Successful access to the necessary arterial sites, successful deployment of all required TAMBE Device components, Patency of all required TAMBE Device components and any required accessory components on completion angiography, absence of surgical conversion within 24 hours of initial of procedure
- Device Integrity, Including Individual Components of Device Integrity [ Time Frame: 12-month ]Components of Device Integrity: Loss of functional patency in any treated branch component due to thrombus or mechanical failure of branch component, loss of functional patency in main body component(s) due to thrombus or mechanical failure of main body components(s) , separation of treated branch component from the main body component(s), separation of the main body component(s) from the accessory components
- Patency (Primary, Assisted Primary, and Secondary) [ Time Frame: 12-month ]Primary Patency - Blood flow without occlusion maintained through the device without an intervention. Assisted Primary Patency: Blood flow maintained through the device after implant regardless of re-interventions performed. Secondary Patency - Blood flow through the device (following occlusion) regardless of re-interventions performed and freedom from surgical bypass.
- Absence of Type I and Type III Endoleaks at One Month Follow-up [ Time Frame: One Month followup ]Absence of Type I and Type III endoleaks
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Aortic aneurysm involving the visceral vessels requiring treatment
- Adequate access for TAMBE Device components
- Appropriate aortic anatomy to receive the TAMBE Device
- Age ≥ 18 years at the time of informed consent signature
- Male or infertile female
- The patient is considered high risk for open repair as deemed by the treating physician
- Capable of complying with protocol requirements, including follow-up
- An Informed Consent Form signed by Subject or legal representative Note: Additional Inclusion Criteria may apply
Exclusion Criteria:
- Prior aortic surgery
- Ruptured or leaking aortic aneurysm
- Aneurysmal dilatation due to chronic aortic dissection
- Infected aorta
- Mycotic aneurysm
- Life expectancy <2 years
- Myocardial infarction or stroke within 6 weeks of treatment
- Systemic infection which may increase risk of endovascular graft infection
- Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome
- Participation in another drug or medical device study within 1 year of study enrollment
- History of drug abuse, e.g. cocaine or amphetamine or alcohol, within 1 year of treatment
- Tortuous or stenotic iliac and / or femoral arteries and the inability to use a conduit for vascular access
- Known sensitivities or allergies to the device materials
- Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin
- Patient has body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta
- Renal Insufficiency Note: Additional Exclusion Criteria may apply
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02528500
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, Missouri | |
Washington University School of Medicine | |
Saint Louis, Missouri, United States, 63110 | |
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756 | |
United States, New York | |
The Mount Sinai Medical Center | |
New York, New York, United States, 10029 | |
United States, North Carolina | |
University of North Carolina Chapel Hill | |
Chapel Hill, North Carolina, United States, 27599 | |
United States, Pennsylvania | |
UPMC | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | Michel Makaroun, M.D. | University of Pittsburgh |
Documents provided by W.L.Gore & Associates:
Responsible Party: | W.L.Gore & Associates |
ClinicalTrials.gov Identifier: | NCT02528500 |
Other Study ID Numbers: |
AAA 13-02 |
First Posted: | August 19, 2015 Key Record Dates |
Results First Posted: | July 3, 2018 |
Last Update Posted: | June 28, 2023 |
Last Verified: | June 2023 |
Aneurysm Aortic Aneurysm Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Thoracic |
Vascular Diseases Cardiovascular Diseases Aortic Diseases Aortic Aneurysm, Abdominal |